EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Biological classification of memory clinic patients

Sophie E Mastenbroek iD, Lyduine E Collij, Toomas Erik Anijärv, Jonathan Rittmo, Alexandra L Young, Olof Strandberg, Ruben Smith iD, Nicola Spotorno iD, Sebastian Palmqvist iD, Niklas Mattsson-Carlgren iD, Shorena Janelidze, Piero Parchi iD und 4 weitere

Brain · 2026

DOI: 10.1093/brain/awaf411 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2026. Verfasst von Sophie E Mastenbroek und 15 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund 222 42, Sweden. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Dementia, Memory Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alzheimer Nederland, European Research Council, Swedish Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neurodegenerative diseases have traditionally been defined in vivo based on clinical symptoms. However, the development of biomarkers has enabled a shift towards in vivo biological definitions. There is now a need to characterize memory clinic populations using multi-dimensional biomarker information. Here, we employed a data-driven approach to develop a biological framework for categorizing individuals in a heterogeneous memory clinic cohort based on the presence, extent and sequence of several common pathologies. We studied 1677 individuals, including subjective cognitive decline (SCD, n = 255), mild cognitive impairment (MCI, n = 400), all cause dementia (n = 393) and cognitively normal controls (n = 625) from the BioFINDER-2 cohort [median age (interquartile range) = 72.0 (16.2) years; 50.3% female]. The Subtype and Stage Inference (SuStaIn) model was applied to biomarkers of amyloid-β (Aβ) (CSF Aβ42/Aβ40), tau (temporal meta-region of interest PET), neuronal α-synuclein [CSF seed amplification assay (SAA)], vascular pathology [MRI-based white matter hyperintensities (WMHs)] and regional atrophy (MRI-based cortical thickness) to identify biomarker-based clusters across the entire dataset. We then applied this framework to cognitively symptomatic individuals (n = 788) to compare clinical symptoms, disease progression rate and brain changes (atrophy and functional connectivity) across profiles. We identified five biomarker clusters reflecting established clinico-pathological entities, closely corresponding to (i) Alzheimer’s disease [AD, n = 317 (40.2%)]; (ii) α-synuclein disease [αSyn, n = 123 (15.6%)]; (iii) vascular disease [Vascular, n = 67 (8.5%)]; (iv) mixed AD and Vascular [Mixed, n = 207 (26.3%)]; and (v) a heterogenous group of individuals characterized by atrophy without any of the major brain pathologies, here termed ‘non-vascular, Alzheimer's, and synuclein pathology' [NOVAS, n = 74 (9.4%)]. The AD profile was characterized by global cognitive impairment and cortical atrophy in AD-associated regions. The αSyn profile was associated with visuospatial and executive dysfunction, motor impairment, hallucinations and functional connectivity disruptions throughout the brain, despite less overall atrophy compared to all others. The Vascular profile showed language and motor impairments, and both the Vascular and Mixed profiles demonstrated atrophy in cingulate and subcortical regions, alongside reduced periventricular white matter integrity. The NOVAS profile was older, demonstrated pronounced hippocampal and amygdala atrophy and baseline memory deficits, possibly reflecting neurodegenerative diseases for which currently no robust biomarkers are available, such as primary tauopathies and TDP-43 proteinopathies [e.g. limbic-predominant age-related TDP-43 encephalopathy (LATE)]. In longitudinal analyses, the AD profile showed the fastest global cognitive decline, while αSyn demonstrated an accelerated decline in language and executive and visuospatial functioning. To conclude, classifying individuals using a multimodal biomarker approach can provide valuable diagnostic and prognostic insights, with potential implications for clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionDementiaMemory DisordersHumansFemaleAgedMaleBiomarkersAmyloid beta-PeptidesMiddle Agedtau ProteinsAged, 80 and overalpha-SynucleinCohort StudiesMagnetic Resonance ImagingAtrophy

Stichwörter der Autor:innen

amyloid-βbiological frameworkdata-driventauvascularα-synuclein

Substanzen

BiomarkersAmyloid beta-Peptidestau Proteinsalpha-Synuclein

Autor:innen und Institutionen

  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund 222 42, Sweden.
  • Department of Radiology and Nuclear Medicine, Vrije Universiteit Amsterdam, Amsterdam University Medical Center location VUmc, Amsterdam 1081 HV, The Netherlands.
  • Amsterdam Neuroscience, Brain imaging, Amsterdam 1081 HV, The Netherlands.
  • Department of Clinical Sciences Malmö, Faculty of Medicine, SciLifeLab, Lund University, Lund 222 42, Sweden.
  • UCL Hawkes Institute, Department of Computer Science, University College London, London WC1V 6LJ, UK.
  • Memory Clinic, Skåne University Hospital, Malmö 205 02, Sweden.

ORCID-Profile: Sophie E Mastenbroek, Ruben Smith, Nicola Spotorno, Sebastian Palmqvist, Niklas Mattsson-Carlgren, Piero Parchi, Oskar Hansson

Förderung

  • Alzheimer Nederland
  • European Research Council
  • Swedish Research Council
  • Knut and Alice Wallenberg foundation
  • Lund University
  • Alzheimerfonden
  • Swedish Brain Foundation
  • Parkinsonfonden

Zitieren

APA

Mastenbroek, S. E., Collij, L. E., Anijärv, T. E., Rittmo, J., Young, A. L., Strandberg, O., Smith, R., Spotorno, N., Palmqvist, S., Mattsson-Carlgren, N., Janelidze, S., Parchi, P., Vogel, J. W., Barkhof, F., Ossenkoppele, R., & Hansson, O. (2026). Biological classification of memory clinic patients. Brain. https://doi.org/10.1093/brain/awaf411

Vancouver

Mastenbroek SE, Collij LE, Anijärv TE, Rittmo J, Young AL, Strandberg O, et al. Biological classification of memory clinic patients. Brain. 2026. doi:10.1093/brain/awaf411

BibTeX
@article{Mastenbroek2026,
  author = {Mastenbroek, Sophie E and Collij, Lyduine E and Anijärv, Toomas Erik and Rittmo, Jonathan and Young, Alexandra L and Strandberg, Olof and Smith, Ruben and Spotorno, Nicola and Palmqvist, Sebastian and Mattsson-Carlgren, Niklas and Janelidze, Shorena and Parchi, Piero and Vogel, Jacob W and Barkhof, Frederik and Ossenkoppele, Rik and Hansson, Oskar},
  title = {Biological classification of memory clinic patients},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awaf411}
}
Kostenlos starten →